Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma

Paul A. Meyers, Joseph A. Ludwig, Matteo Trucco et al.|Journal of Clinical Oncology|2024

Cited by 36